Close

Press Releases

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

SEQENS, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, announced a multi-million-dollar investment in its research and development laboratory located in Devens, Mass. The improvements will ensure that the new facility will operate at the...

Phlow to Provide Manufacturing R&D Services for Small Molecule Pharmaceutical Product Development in the Commercial Sector

Phlow Corp., a U.S.-based essential medicines public benefit company, announced strategic alliances with both Virginia Commonwealth Universityโ€™s (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule...

Sen-Jam Pharm Partners with Specialty Pharma Manufacturer to Provide Formulation and Chemistry, Manufacturing & Controls for Covid-19 Oral Therapeutic

Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, has entered a strategic partnership with KVK Tech. KVK Tech is a leading Specialty Pharmaceutical Manufacturing company that...

Gamma Biosciences Launches Initiative Through Mirus Bio to Develop Lipid-Polymer Nanocomplexes for In Vivo mRNA Delivery

Gamma Biosciences, a global life sciences company serving the advanced therapy market, announced an initiative through its subsidiary Mirus Bio, a leader in nucleic acid delivery technology, to develop novel, highly active lipid-polymer nanocomplexes for therapeutic mRNA delivery in...

Pfizer to supply UNICEF up to 4 million treatment courses of novel Covid-19 oral treatment, Paxlovid for low- and middle-income countries

Pfizer Inc. announced an agreement with UNICEF to supply up to 4 million treatment courses of its Covid-19 oral treatment, Paxlovid (nirmatrelvir tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval. This includes...

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, and Biolexis, a division of Stelis Biopharma Limited (Stelis), announced that they have entered into a licensing, manufacturing and commercialization agreement for Akstonโ€™s AKS-452, a protein subunit COVID-19...

Peli BioThermal Launches Updated Credo ProEnvision Software

Peli BioThermal, the life science industryโ€™s cold chain partner from discovery to distribution, announces a growing number of enhancements to its CredoProEnvision track and trace software. CredoProEnvision 2.0 lays the groundwork for more significant software updates as Peli BioThermal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป